Pfizer's Sutent Receives Dual Approvals For Kidney Cancer & Stomach Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer's Sutent received accelerated approval for first-line treatment of advanced renal cell carcinoma and full approval for treatment of refractory gastrointestinal stromal tumors.